Strata Critical Medical, Inc.SRTAEarnings & Financial Report
Strata Critical Medical, Inc. is a medical technology firm designing, producing and distributing disposable medical products for critical care, anesthesia and surgical use cases. It serves healthcare providers across North America and some European markets, focusing on improving patient safety and clinical efficiency.
SRTA Q4 FY2025 Key Financial Metrics
Revenue
$22.7M
Gross Profit
$-203.0K
Operating Profit
$-4.2M
Net Profit
N/A
Gross Margin
-0.9%
Operating Margin
-18.4%
Net Margin
N/A
YoY Growth
361.2%
EPS
$-0.11
Strata Critical Medical, Inc. Q4 FY2025 Financial Summary
Strata Critical Medical, Inc. reported revenue of $22.7M (up 361.2% YoY) for Q4 FY2025, with a net profit of N/A (N/A margin). Cost of goods sold was $22.9M, operating expenses totaled $4.0M.
Key Financial Metrics
| Total Revenue | $22.7M |
|---|---|
| Net Profit | N/A |
| Gross Margin | -0.9% |
| Operating Margin | -18.4% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Strata Critical Medical, Inc. Q4 FY2025 revenue of $22.7M breaks down across 3 segments, led by Other Clinical at $11.4M (50.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other Clinical | $11.4M | 50.1% |
| Transplant Clinical | $9.0M | 39.4% |
| Other | $2.4M | 10.5% |
Strata Critical Medical, Inc. Annual Revenue by Year
Strata Critical Medical, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $197.1M).
Strata Critical Medical, Inc. Quarterly Revenue & Net Profit History
Strata Critical Medical, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $22.7M | +361.2% | N/A | N/A |
| Q3 FY2025 | $49.3M | +36.7% | $57.4M | 116.5% |
| Q2 FY2025 | $70.8M | +4.2% | $-3.7M | -5.3% |
| Q1 FY2025 | $54.3M | +5.4% | $-3.5M | -6.4% |
| Q4 FY2024 | $-8.7M | -118.3% | N/A | N/A |
| Q3 FY2024 | $36.1M | -49.5% | $-2.0M | -5.4% |
| Q2 FY2024 | $67.9M | +11.4% | $-11.3M | -16.7% |
| Q1 FY2024 | $51.5M | +13.8% | $-4.2M | -8.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $51.5M | $67.9M | $36.1M | $-8.7M | $54.3M | $70.8M | $49.3M | $22.7M |
| YoY Growth | 13.8% | 11.4% | -49.5% | -118.3% | 5.4% | 4.2% | 36.7% | 361.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $282.8M | $280.3M | $282.9M | $256.7M | $250.6M | $257.9M | $335.1M | $325.5M |
| Liabilities | $46.2M | $50.9M | $49.4M | $34.7M | $30.8M | $34.8M | $52.1M | $46.4M |
| Equity | $236.6M | $229.4M | $233.5M | $221.9M | $219.7M | $223.1M | $283.0M | $279.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-15.6M | $8.4M | $6.4M | $-1.8M | $-246000 | $-3.1M | $-37.3M | $-8.3M |